Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

9.875
+0.2652.76%
Volume:577.00K
Turnover:5.67M
Market Cap:10.39B
PE:-26.68
High:9.950
Open:9.560
Low:9.560
Close:9.610
52wk High:19.860
52wk Low:7.950
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:0.31
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.370
ROE:-18.45%
ROA:-14.45%
PB:4.60
PE(LYR):-26.68
PS:4389.61

Loading ...

ASCLETIS-B Chooses Fixed-Dose Combination of Pioneering Oral Small Molecule GIPR Agonist ASC48 and Oral GLP-1R Agonist ASC30 for Clinical Development

Stock News
·
Jul 15

Ascletis Pharma - Selects Fixed-dose Combination of Asc48 and Asc30 for Clinical Development

THOMSON REUTERS
·
Jul 15

Ascletis Accelerates Buyback: Acquires 0.20 Million Shares for HK$2.09 Million, Lifts 2026 Repurchase Total to 0.55 Million

Bulletin Express
·
Jul 14

ASCLETIS-B (01672) Allocates HK$2.09 Million for Share Buyback on July 14

Stock News
·
Jul 14

Ascletis Pharma Files HKEX Next-day Disclosure Return on Share Repurchase for Cancellation

Reuters
·
Jul 14

Biotech Stocks Surge as New National Essential Drug List Includes Innovative Therapies

Stock News
·
Jul 10

ASCLETIS-B Executes Share Buyback, Spending HK$1.119 Million

Stock News
·
Jul 08

Race to Launch Weight-loss Pills Heats up as Smaller Players Advance

Reuters
·
Jul 08

Ascletis Pharma Completes HKD 1.15 Million Buyback; Uncancelled Repurchased Shares Reach 9.63 Million

Bulletin Express
·
Jul 07

ASCLETIS-B Executes Share Buyback on July 7, Spending HK$1.153 Million

Stock News
·
Jul 07

Ascletis Pharma Files HKEX Next-day Disclosure Return on Share Repurchase for Cancellation

Reuters
·
Jul 07

Ascletis Pharma Submits Two Obesity Drug Applications to US FDA

MT Newswires Live
·
Jul 06

Ascletis Pharma to Use up to Hk$300 Million for Share Repurchase

Reuters
·
Jul 06

Ascletis Hits 5-week High on New Drug Applications for Obesity Treatment

Reuters
·
Jul 06

Is Ascletis Pharma (SEHK:1672) Undervalued As FDA Clears Its ASC35 Obesity Trial?

Simply Wall St.
·
Jul 06

ASCLETIS-B Submits Two IND Applications to US FDA for Obesity Treatments: Monthly Peptide Amylin Receptor Agonist ASC36 and ASC36_35 Combination Monthly Injection

Stock News
·
Jul 06

Ascletis Submits Two Obesity-drug IND Applications to US FDA for Asc36, Asc36_35 FDC Injections

Reuters
·
Jul 06

Ascletis Pharma - Submits Two Ind Applications to U.S. FDA for Obesity Treatment

THOMSON REUTERS
·
Jul 06

Ascletis Pharma Maintains Stable Share Capital Structure in June 2026; Public Float Above 25% Threshold

Bulletin Express
·
Jul 03

Ascletis Pharma Discloses 145,000-Share Buyback on 30 June; Outstanding Shares Steady at 1.06 Billion

Bulletin Express
·
Jun 30